Barry O'Leary, CEO, IDA
Upcoming SlideShare
Loading in...5
×
 

Barry O'Leary, CEO, IDA

on

  • 562 views

 

Statistics

Views

Total Views
562
Views on SlideShare
562
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Barry O'Leary, CEO, IDA Barry O'Leary, CEO, IDA Presentation Transcript

  • Barry O’LearyCEO IDA IrelandOctober 31 2012
  • Current Impact of FDIIDA Portfolio Companies250,000€115 billion
  • Current Impact of FDI Two thirds Business Expenditure on R&D
  • IDA Business Focus
  • IDA focus across industry segmentsLeading MNCs2nd TierEmerging Companies
  • Some wins to-date: January – October 2012
  • Ireland – Pharma / BioPharma Cluster
  • Lifescience Shared Services
  • Key Recent Pharma/Biopharma Investments New Expansion of Galway & Dublin;biopharmaceutical development and Expansion of Sligo Development, Dun Laoghaire facility in Cork manufacturing Pharmaceutical Manufacturing and Facility in Dublin operations Plant Supply Chain $200m / 100 Jobs Management$420m / 200 Jobs $350m / 200 Jobs $110m / 175 Jobs $ 500m / 500 Jobs Bioassay Centre of Expansion of European HQ Sales Cork Manufacturing Expertise biotech campus in and Manufacturing Plant /Pneumococcal Grange Castle, Base Vaccine Conjugation Dublin $50m / 100 jobs Facility 120 jobs €29m $200m
  • Initiatives to support Pharma / Biopharma Cluster  Solid State Pharma Cluster ACADEMIA INDUSTRY  Pharmaceutical Manufacturing Technology Centre  National Institute for Bioprocessing Research and Training (NIBRT)
  • What attracts FDI to Ireland?• Talent, Technology, Track Record (operational excellence), Tax,• Ease of doing Business , EU Access, English speaking are building blocks…• Sector / Activity / Country Specific• Ireland’s Value Proposition - Needs Constant Enhancement Example – Biopharmaceuticals; - FDA Track Record TEAM IRELAND - National Institute for Bioprocessing and Research Training (NIBRT) - Science Foundation Ireland Initiatives - Strategic Sites - Cluster Impact - Financial Incentives - Regulatory Environment
  • World Competitiveness RankingsIBM PLI Global Location Trends Report 2011; 2nd ranked destination by jobs per 100,000 inhabitants 1st ranked destination by value* of Investment projects * a combination of Productivity, value-added, knowledge intensity and occupational profile composition Up 4 Places to Number 20IMD World Competiveness Yearbook 2012 1st in the world for ready availability of skilled labour 1st for flexibility and adaptability of people to challenges 1st for investment incentives to attract foreign investors 2nd for positive attitudes towards globalization 2nd for adaptability of companies to market changes 3rd for unit labour costs in the manufacturing sector 3rd in the world for labour productivity 4th for corporate tax rate on profit
  • FDI Outlook• Good immediate pipeline in Technology (ICT) Sector, Lifesciences, Financial Services, Digital media / Content, Professional / International Services• Flat European Market – Importance for FDI – Global Outlook• IDA needs to have more than 100+ investments in play at any one time• Pipeline generation and conversion is a key focus
  • Thank You